SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ:PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported revenues for the fiscal quarter ended October 31, 2009 of $221,900 compared with revenues of $110,600 in the same quarter of the prior fiscal year. The Company reported a net loss of $(1,711,200), or $(0.05) per share, for the current quarter compared with a loss of $(1,605,300), or $(0.05) per share, in the first fiscal quarter last year.
